Filing Flows › Kymera Therapeutics (KYMR) › Recalls, complaints & regulation
Kymera Therapeutics (KYMR): EPA violations and clinical trials
Kymera Therapeutics (KYMR) beyond its filings: 0 EPA-regulated facilities in violation, $8K in penalties over five years; 4 active clinical trials.
Kymera Therapeutics' latest quarter
Kymera Therapeutics, Q2 2026: revenue $65.0M (+466% year over year), operating margin -116.3%, net loss $61.2M, operating cash flow −$54.1M. The chart follows the revenue to costs, profit and cash.
Questions
Has Kymera Therapeutics been fined by the EPA?
The 2 EPA-regulated facilities on file under its name drew $8K in penalties over five years; 0 are in violation now.
How many clinical trials does Kymera Therapeutics have?
4 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.